AstraZeneca Pharma India is the Indian arm of the global biopharmaceutical giant, and its business is fundamentally about bringing patented, innovative prescription medicines to the Indian market - it does not make generic drugs. Incorporated in 1979 and operating for over 45 years, the company has recently pivoted to a pure specialist-care model, shutting its own manufacturing plant to focus entirely on selling and distributing high-science therapies imported or packaged locally. The recurring approach that explains everything else is a “Growth through innovation strategy,” where the company bets on first-in-class molecules, builds physician preference through international clinical guidelines, and then defends its brands even after patents expire by leveraging the trust of specialist doctors. # Business segments Three specialist therapy engines, all selling innovative prescription medicines to the same Indian healthcare system - an oncology powerhouse, a diversified biopharma portfolio, and a nascent rare-disease unit - supported by a clinical-trial services line that works for its global parent. ## 1. Oncology Business Unit: the company’s growth engine and India’s top-three cancer drug franchise **A portfolio of 11 patent-protected molecules targeting a wide spectrum of tumours has made AstraZeneca one of the top three oncology companies in India, with the unit growing at double-digit rates year after year.** - **Lung cancer is the anchor** - Tagrisso, a targeted therapy for a specific genetic mutation in lung cancer, is the company’s largest oncology brand and one of the top five cancer drugs in India, so strong that a strategic price cut in 2022 led to a 40% jump in new patients. - **Immunotherapy adds a second pillar** - Imfinzi, another top-five oncology brand, is the first and only approved immunotherapy for a specific stage of inoperable lung cancer, and its use is being expanded into new tumour types like gastrointestinal and liver cancers through fresh clinical approvals. - **Breast cancer is the new frontier** - Enhertu, a drug for a tough-to-treat form of breast cancer, was launched in early 2024 and became a top-ten oncology brand in India within its first year, crossing ₹200 crore in sales because it addressed a clear unmet need. - **The pipeline feeds the franchise** - the unit keeps launching new drugs like Calquence for blood cancers and Imjudo for liver cancer, while older drugs like Lynparza, once the leader in ovarian cancer, face value erosion after more than 16 generic copies entered the market upon patent expiry. - **Diagnosis drives demand** - the company partners with AI firms for lung cancer screening in Karnataka’s district hospitals and with testing labs for biomarker identification, because finding more patients early is what creates the market for its targeted therapies. ## 2. Biopharmaceuticals Business Unit: a diversified portfolio of market-leading legacy and biologic medicines **This unit holds the number-one position in key chronic therapy markets despite fierce generic competition, while pivoting toward newer biologic drugs and innovative inhalers for specialist care.** - **Market leader even after patent expiry** - Brilinta, a blood thinner, has faced over 35 generic competitors since losing exclusivity in 2019, yet it remains the market leader by value and still grew 12% in FY25 because cardiologists stick with the brand they trust. - **The diabetes drug that dominates** - Forxiga is the number-one brand of its molecule in India even though it competes with more than 120 generic versions, and it was the first drug in its class approved for both heart failure and chronic kidney disease, which expanded its use beyond diabetes. - **Biologics are the high-growth wedge** - Fasenra, the company’s first biologic in India for severe asthma, already commands a 46% value market share and grew at 79%, because pulmonologists see it as the most effective and convenient option for a hard-to-treat patient group. - **New delivery technology creates differentiation** - Breztri, a new triple-combination inhaler for COPD launched in early 2025, uses a proprietary device that delivers roughly 50% of the drug to the lungs, and over 1,500 patients were put on it in the first quarter alone. - **Partnerships extend reach for older brands** - Symbicort, an established inhaler, is now distributed by Mankind Pharma under an exclusive five-year deal where AstraZeneca keeps the intellectual property and import licence, and the brand grew 48% under this arrangement because it taps Mankind’s wider sales network. ## 3. Rare Disease Unit: a new bet on first-in-class therapies for untreated conditions **Launched in 2023, this unit brings the first-ever approved treatments for specific rare diseases to India, where no options existed before, and builds the market by working with patient groups and the government.** - **First and only for a childhood tumour condition** - Koselugo is the sole approved therapy in India for children with a genetic disorder that causes inoperable nerve tumours, so it serves a patient population that previously had no medical answer. - **A second launch opens a new disease area** - Soliris, India’s first anti-complement therapy, was launched in August 2025 for two rare and life-threatening blood disorders, giving the unit a foothold beyond its initial single-drug offering. - **Advocacy creates the ecosystem** - the company works with organisations like the Organization for Rare Diseases India and disease-specific foundations, and engages with the government to widen the National Policy for Rare Diseases, because for rare diseases, building awareness and policy support is as critical as having the drug. # Clinical Trial Services **A distinct, fee-based business line that runs clinical trials in India for the global AstraZeneca group, generating revenue on a cost-plus basis without taking on drug-development risk.** - **Paid for work done, not for success** - the company charges its overseas group company based on actual costs incurred as trial services are performed, so revenue is recognised as the work progresses and the model is insulated from whether a drug ultimately succeeds. - **India’s patient pool is the asset** - the services are provided to AstraZeneca Pharmaceuticals AB, Sweden, leveraging India’s large and diverse patient population to support the global pipeline, which is why this line accounted for 6.1% of total revenue in FY25. - **Integrated with the parent, not a standalone business** - the company also receives reimbursements for personnel on assignment and for marketing and promotion costs tied to these studies, making this a tightly linked service arm rather than an independent contract research organisation. # Group structure and partners **AstraZeneca Pharma India is a subsidiary of the global AstraZeneca group, with no subsidiaries of its own, and it manages its Indian market through a mix of direct sales and distribution partnerships while having recently exited its own manufacturing.** - **The holding chain runs through Sweden** - the company is ultimately controlled by AstraZeneca PLC in the UK, with the immediate parent being AstraZeneca Pharmaceuticals AB, Sweden, and the Board has three directors representing the parent company alongside independent and executive directors. - **Deep sourcing ties with the parent** - the company buys its raw materials and traded goods from AstraZeneca group companies in the UK and Sweden under a long-standing agreement dating to 2005, with credit terms of 120 days, and the value of these purchases has historically exceeded 10% of the company’s turnover. - **Partnerships for wider distribution** - a five-year deal with Mankind Pharma gives Symbicort access to a mass sales force while AstraZeneca retains the brand ownership, and a similar arrangement with Sun Pharma for a new hyperkalaemia drug sees both companies selling the same molecule under different brand names, with AstraZeneca receiving an upfront and milestone payment of ₹26 crore. - **Manufacturing is now outsourced** - the company’s Bangalore plant, which ran on 95-97% green energy with zero effluent discharge, ceased operations in mid-2025 and is being sold, with products transitioning to an alternative supply site to maintain uninterrupted supply.